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systematic review
Danish Abdul Aziz,1 Syeda Khadija Fatima,2 Hasan Nawaz Tahir3

Abstract

Introduction

Objective: To ascertain major risk factors associated with
pulmonary exacerbation and pulmonary function decline
in cystic fibrosis.

Cystic fibrosis (CF) is an inherited disorder affecting
multiple organ systems. Autosomal recessive mutation of
the cystic fibrosis transmembrane conductance regulator
(CFTR) gene on chromosome 7 plays a pivotal role in
pathogenesis. Major morbidity and mortality are
attributed to pulmonary manifestations of CF. Infections
comprise the major lung disease burden. Structural and
functional decline in pulmonary parenchyma occurs with
recurrent pulmonary exacerbations. In the United States,
1 out of every 3,200 Caucasian births have CF. Current
medical advancements and research developments have
increased median survival to the 4th decade. However,
patients still experience shortened life expectancy
secondary to devastating pulmonary manifestations and
progressive lung function decline.1

Method: The systematic review was conducted at Aga
Khan University, Karachi, in September 2018, and
comprised electronic search of PubMed, Ovid, Science
Direct and Cumulative Index of Nursing and Allied Health
Literature databases of studies conducted from January
1990 to September 2018 which were categorised into 3
sets; 1990-98, 1999-2007 and 2008-18. Studies included
for review focussed on articles with pulmonary
exacerbation as the health outcome indicator, and had
diagnosis of cystic fibrosis as the inclusion criteria, while
risk factors were the exposure terms used in the search
process. References in bibliographies of the included
studies were also systematically searched for relevant
documents.
Results: Of the 60 studies obtained, 31(51.7%) were
selected; 2(6.45%) from 1990-98, 7(22.58%) from 19992007 and 22(70.96%) from 2008-18. Overall, 17(54.83%)
were cohort studies, 7(22.5%) were cross-sectional
studies, 3(9.6%) were case-control studies, 3(9.6%) were
randomised controlled trials and 1(3.2%) was systematic
review and meta-analysis. In terms of major risk factors,
genetic mutations were cited by 4(12.9%) studies,
infections and inflammatory biomarkers by 15(48.4%),
nutritional deficiencies by 9(29%) and geographical and
socioeconomic status by 3(9.6%) studies.
Conclusion: Early identification and recognition of risk
factors associated with pulmonary exacerbation can have
an explicit impact on its management, leading to
decreased morbidity and mortality burden in cystic
fibrosis cases.
Keywords: Pulmonary exacerbation, Cystic fibrosis, Risk
factors, Systematic review.
DOI: https://doi.org/10.47391/JPMA.04-515

Pulmonary exacerbation is as an escalation of the
pulmonary decline with deterioration in forced expiratory
volume in 1 second (FEV1), nutritional decline, regression in
daily functioning and quality of life (QOL). Progressive lung
descent is the central determinant of disease outcome in
CF.2 Pulmonary exacerbation serves as a key indicator for
disease severity and is a crucial variable in studies assessing
overall survival (OS) related to CF. Moreover, lung disease
remains the primary target for pivotal treatments
decreasing morbidity and mortality in CF. Multiple risk
factors associated with pulmonary manifestations
contributing to exacerbations have been identified. These
include nutritional deficiencies, infections, medications,
biochemical markers indicating acute episodes and the
effect of socioeconomic status (SES).3
Identification of risk factors has a vital role in treatment and
can improve management outcomes in CF population
which in turn can affect life-expectancy and rate of
exacerbations.
The current study was planned to systematically review
literature to recognise risk factors correlated with
pulmonary exacerbations in CF.

Methods
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The systematic review was conducted at Aga Khan
University, Karachi, and comprised electronic search of
PubMed, Ovid, Science Direct and Cumulative Index of
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Nursing and Allied Health Literature (CINAHL) databases
of studies conducted from January 1990 to September
2018 which were categorised into 3 sets; 1990-98, 19992007 and 2008-18. The year 1990 was set as the starting
point for literature search to maintain relevance.

initial electronic search carried out independently by all the
authors, decisions and abstracted summaries were
compared and disparities were settled through discussion.
For the development of protocol, manuscript and reporting
of study findings, Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines were
used.4 Quality assessment of the studies was done using the
Newcastle-Ottawa scale (NOS) for cross-sectional and
cohort studies,5 interpreted as per the given criteria; Good
quality: 3 or 4 stars in selection domain AND 1 or 2 stars in
comparability domain AND 2 or 3 stars in
outcome/exposure domain; Fair quality: 2 stars in selection
domain AND 1 or 2 stars in comparability domain AND 2 or
3 stars in outcome/exposure domain; Poor quality: 0 or 1
star in selection domain OR 0 stars in comparability domain
OR 0 or 1 stars in outcome/exposure domain". Cochrane risk
of bias tool was used for interventional studies.6

The initial database search was done in September 2018
followed by screening of articles. The review of relevant
full text completed in the last quarter of 2018, and the
manuscript was finalised in the first quarter of 2019.
The search covered all reports in indexed and nonindexed local and international English-language journals
which described primary epidemiological research
concerning risk factors for pulmonary exacerbation in CF
in Asian populations. Studies included for review
focussed on articles with pulmonary exacerbation as the
health outcome indicator, and had diagnosis of cystic
fibrosis as the inclusion criteria, while risk factors were the
exposure terms used in the search process. References in
bibliographies of the included studies were also
systematically searched for relevant documents.
Full-text copies of all the studies found were scrutinised.
Those that met the inclusion criteria were then abstracted
and summarised using a standardised form. Following the

In assessing publications apposite for review, findings
were assembled by health outcomes, and conclusions
were measured that could be drawn given the strengths
and limitations of each study.

Results
Of the 60 studies obtained, 31(51.7%) were selected

Figure: Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow-chart.
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Table-1: Duration and type of studies.
Total of n=31 studies included, from 1990-2018. The timeline was divided into three
stages:
- 1990-1998= 2 studies
- 1999-2007=7 studies
- 2008-2018=22 studies
- Cohort studies=54.83% (17)
- Cross-sectional studies=22.5 % (7)
- Case-control studies= 9.6 % (3)
- Randomized controlled trials= 9.6 % (3)
- Systematic Reviews/Meta-analysis= 3.2 % (1)
Table-2: Themes for analysis.
Risk factors associated with Pulmonary exacerbation in Cystic Fibrosis: (n=31)
- Genetic mutations (n=4)
- Infections and Inflammatory biomarkers (n=15)
- Nutritional deficiencies (n=9)
- Geographic and socioeconomic status (n=3)

(Figure). Of them, 2(6.45%) were from the 1990-98 period,
7(22.58%) from 1999-2007 and 22(70.96%) from 2008-18.
Overall, 17(54.83%) were cohort studies, 7(22.5%) were
cross-sectional studies, 3(9.6%) were case-control studies,
3(9.6%) were randomised controlled trials (RCTs) and
1(3.2%) was systematic review and meta-analysis (Table1). Of the 17(54.83%) cohort studies, 13(76%) were of
good quality and the remaining 4(24%) had fair quality.
All the 7(22.5%) cross-sectional studies had good quality.
In terms of major risk factors, genetic mutations were
cited by 4(12.9%) studies, infections and inflammatory
biomarkers by 15(48.4%), nutritional deficiencies by
9(29%) and geographical location and SES by 3(9.6%)
studies (Table-2).
In terms of genetic mutations, a 2011 study analyzed
correlation between CFTR class I and class II mutations in
CF patients, and determined that two class I mutations
were linked with grave pulmonary functional decline in
contrast to two class II mutations or combination of
classes I and II.7 A 2002 study proposed that pulmonary
disease showed an association with severity of CFTR
mutations. Precarious disease with earlier onset (1.7 years
vs 7.9 years, p=0.0001) was seen in patients with two
severe mutations, and they displayed critical respiratory
impairment, mean FEV1 decline (29% of predictive value
vs 58% of predictive value, p<0.001); high pseudomonas
(P.) colonisation (97% vs 57%, p<0.01); prominent
occurrence of end-stage respiratory disease, having FEV1
<30% (73% vs 29%, p<0.05); and with pronounced
regression of FEV1 (3% vs 1.4%, p<0.001) annually.
Multivariate logistic regression analysis, containing two
extreme mutations, was self-governing indicator of an
J Pak Med Assoc
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existence constraining respiratory deficiency (relative
hazard, 6.75; 95% confidence interval [CI] 1.79-26.50,
p=0.003).8
A retrospective observational study in 2015
demonstrated that mean yearly deterioration in FEV1%
predicted was 1.01%. Homozygous F508del mutations
showed a large decrease in FEV1. Moreover, pulmonary
regression was associated with female gender, low body
mass index (BMI), recurrent/productive cough, one or
more pulmonary exacerbation, high FEV1 (>/=115%
predicted), methicillin-sensitive staphylococcus aureus
(MSSA), methicillin-resistant staphylococcus aureus
(MRSA) or stenotrophomonas (S.) maltophilia-positive
cultures.9 A 1997 study, with a large cohort from CF
database, showed that the patients deceased prior to age
15 had a considerably reduced lung function compared to
their first test and had a fleeting drop in pulmonary
function. Lung deterioration was pronounced in delta
F508 mutation homozygotes compared to delta F508
mutation heterozygotes. Females had a noteworthy
precipitous waning than males, and those with pancreatic
insufficiency had exorbitant regression than those with
good pancreatic function.10
Infections and inflammatory biomarkers were identified
by 15(48.4%) studies. A prospective 2004 study
established that a new pulmonary exacerbation in
majority of patients was not secondary to the attainment
of new P. aeruginosa strain. Further, 40(48%) patients
required intravenous (IV) antibiotics for exacerbation,
while 36(43%) patients had genetically typeable P.
aeruginosa isolates, amd in 34(96%) of these 36 patients,
strains recovered during exacerbation and clinical
stability were of the same genotype. Only 2(6%) patients
(95% CI 0-18%) had clone P. aeruginosa strain cultured
during exacerbation.11 A multicentre study in 2014 found
a correlation between P. aeruginosa phenotypes during
infection stages and their prognostic value in pulmonary
exacerbation prediction. It concluded that two in vitro
phenotypes differentiated early and late stages of
infection: pyoverdine production (31% of new cultures,
48% of intermittent, 69% of chronic) and low protease
production (31%, 39%, 65% respectively). Mucoidy (odds
ratio [OR] 1.75, 95% CI 1.19-2.57) and reduced twitching
motility (OR 1.43; 95% CI 1.11-1.84) were strong predictors
for succeeding exacerbations in the following 2 years.12 A
review in 2012 set out to assess the effectiveness of
antibiotics in patients with chronic Burkholderia cepacia
complex infection, determining it as a distinguishing
infection in CF population, and found a deficiency of trial
evidence to establish definite results.13
A cross-sectional and retrospective cohort in 2011

2220

Risk factors leading to pulmonary exacerbation in patients with cystic fibrosis: A systematic review

recognised stenotrophomonas (S.) maltophilia as an
autonomous risk factor for pulmonary decline. Patients
infected chronically with S. maltophilia were found to
have mean antibody titers to bacterial flagellin (p<0.0001)
and antibody titers to whole bacterial cell (p=0.0004)
substantially high compared to patients with no or
intermittent infections. Pulmonary exacerbation risk
demanding hospitalisation and antibiotics was noticeable
in patients infected with S. maltophilia compared to
uninfected patients (relative risk [RR] 1.63, p=0.0002).14 A
prospective study in 2013 recognised a marked risk of
pulmonary exacerbation with viral infections (OR 2.19,
95% CI 1.56-3.08, p<0.001) and antibiotic need in CF
patients (OR 2.26, 95% CI 1.63-3.13, p<0.001).15

determinants were IL-6, IL-8 and sputum neutrophil
elastase.19 A study in 1999 concluded that OS, activity of
free radicals and subsequent damage and their response
to treatment parameters were high during pulmonary
exacerbations and showed
improvements with
treatment.20

The remaining 10(66.6%) studies in the category were
related to biomarkers. A cohort study in 2015, conducted
to find blood-based biomarkers to foresee impending CF
pulmonary exacerbations using specific proteomics,
established the likelihood of imminent exacerbations
prediction with the use of multiple reaction monitoring
mass spectrometry (MRM-MS) in which protein panel
(area under the curve [AUC] 0.74) had the AUC in contrast
to FEV1% predicted (AUC 0.55), C-reactive protein (CRP)
(AUC 0.61) and interleukin-6 (IL-6) (AUC 0.60) which were
the chief biomarkers correlated in exacerbation
prediction.16 A case-control study in 2007 found a rise in
OS and sputum levels of bioactive lipid mediators during
an exacerbation. The sputum 8-iso-prostaglandin F2a (8iso-PGF2a) levels were high in acutely ill CF patients
(p<0.001) along with high cysteinyl leukotrienes (cys-LT)
and prostaglandin E2 (PGE2) levels. Sputum total cell
count (p=0.03) regressed with antibiotic treatment, but 8iso-PGF2a, cys-LT or PGE2 levels remained unaffected,
indicating the need of also addressing this respective
aspect of CF management.17 A cohort in 2014 concluded
that 37(70%) of 53 patients suffered pulmonary
exacerbations during the study period. At baseline,
reduced pulmonary function, lower clinical scoring and
QOL values were related with increased risk of
exacerbation events. Pulmonary exacerbations were
associated with increased inflammatory markers at
baseline on the first day, and treatment led to
improvements in the levels of biomarkers. CRP and IL-8
were the main biomarkers identified and they correlated
with an early re-exacerbation.18
A double-blinded RCT concluded that subjects treated
with liposomal prostaglandin E1 (TLC C-53) had a less
rapid pulmonary functional decline compared to controls
(FEV mean difference 4.3%, 95% CI -6.8-15.4%) and had
more time till next exacerbation (26 weeks against 11.9
weeks). The biomarkers used as primary outcome

A cohort study measured levels of desmosine in the
sputum of CF patients during pulmonary exacerbation
treatment, and established significant decrease in
desmosine during the first week of hospitalisation
(p=0.04). A definite association was found in desmosine
levels, plasma CRP (p=0.59; p=0.03), sputum IL-8 (p=0.86;
p<0.01), and sputum neutrophil elastase (p=0.78,
p<0.01).21 A prospective study in 2011 aimed at
establishing the role of baseline procalcitonin levels in CF
paediatric population and relation of the values with
onset of pulmonary exacerbation. It established that
baseline procalcitonin (n=92) was 0.05±0.07ng/ml, and at
admission for in-patient management of exacerbation
(m=22) it was 0.07±0.06ng/ml; not distinct from levels
reported in healthy children.22 A cross-sectional study in
2014 established the role of soluble cluster of
differentiation 14 (sCD14) as a biomarker in recognising
patients at risk of experiencing a CF exacerbation. It found
sCD14 levels high during exacerbations (p=0.03) and in
patients with IV antibiotics due to exacerbation within 4
months of a steady clinical course (p=0.001).23
An observational study in 2010 established a reduction in
sputum calprotectin after treatment of an exacerbation
(p<0.05). A substantial decrease was found in serum levels
of calprotectin (p=0.002), CRP (p=0.002) and vascular
endothelial growth factor (VEGF) (p=0.013). Moreover,
serum calprotectin showed predictive value for interval
towards next exacerbation (p=0.032) post-treatment.24
One study in 2000 studied an elevation in mean VEGF
levels in pulmonary disease patient groups, including CF
and other lung diseases, and compared reference values,
finding higher VEGF in CF (p=0.02). The study showed an
inverse relation between VEGF and FEV1 in CF, (r-0.51,
p=0.007). Following antibiotics, VEGF levels regressed in
CF exacerbation (p=0.001).25
With respect to nutritional sdeficiencies, a 2014 study
using the CF database established that low BMI,
pancreatic insufficiency, CF-related diabetes and P.
aeruginosa infection had significant (p<0.001) impact on
FEV1. Patients with low BMI had higher OR (95% CI 5.07.3) of experiencing a debilitating pulmonary decline,
pancreatic insufficiency had more risk (95% CI 1.6-2.5) and
two-fold increase in OR of severe lung disease, and CFrelated diabetes patients had 1.8 times increased OR (95%
CI 1.6-2.2) in contrast to unaffected patients.26 A cohort
Vol. 71, No. 9, September 2021
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study in 2008 indicated a gradual rate of pulmonary
deterioration in patients with good nutritional state,
slower BMI decline, lack of P. aeruginosa infection and
Dornase alfa (Pulmozyme) therapy introduction at an
early age.27
A prospective, observational study in 2013 established a
positive association between stronger pulmonary system
at 6-18 years of age and weight-for-age percentile (WAP)
>10% at age 4. Patients aged 18 years with WAP >50% at
age 4 had less acute exacerbations, limited hospital stay
and lower rate of diabetes. Good weight during
childhood correlated with greater height, better
pulmonary function, reduction in CF complications and
improved survival through age 18.28
With respect to vitamin D, a 2016 RCT indicated that highdose vitamin D3 had anti-catabolic effects in pulmonary
exacerbations of CF.1 Another RCT done in 2012 showed a
decrease in inflammatory markers, like tumour necrosis
factor-alpha (TNF-a) (p<0.001, 50.4% decrease) and IL-6
(p=0.09, 64.5% decrease) in subjects given high-dose
vitamin D during an exacerbation, supporting the role of
vitamin D in inflammation regulation.29 An ongoing RCT is
assessing the impact of vitamin D in CF-related
pulmonary exacerbation, but is yet to publish its findings1
A cohort study in 2013 indicated that vitamin D-deficient
patients had a substantially higher rate of exacerbations
(13.1/10) patient-year compared to patients with vitamin
D insufficiency (4.3/10) patient-year.30 One case-control
study in 2012 showed pronounced bacterial colonisation
in vitamin D-deficient patients (p<0.001) along with
increased airway inflammation with increased markers
myeloperoxidase (MPO) (p=0.007), IL-8 (p<0.001), TNF-a
(p=0.03) and FEV1 decline.31
A cross-sectional study in 2016 evaluated folate and
vitamin D deficiency, and found an enhanced degree of
atopy in patients with folate deficiency and a 2.2 times
odd of acquiring at least one asthma exacerbation (95% CI
1.1-4.6). Patients with both folate and vitamin D
insufficiencies had eight-fold amplified OR of one or
more severe asthma exacerbation (95% CI 2.7-21.6).32
A cohort study in 1996 assessed vitamin A status and
suggested plasma retinol concentrations regressed in
acute pulmonary exacerbation. Overall, 8 of 35 subjects
had plasma retinol levels in the deficient range
(<0.07micromol/L), mean concentrations of plasma
retinol-binding protein (RBP) increased during
hospitalisation (1.46 to 2.24 micromol/L), and CRP
declined.33 Another study in 2004 indicated a very large
cohort of CF being deficient in antioxidants.
Deficiencies of carotenoids and vitamin E occurred in
J Pak Med Assoc
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early disease, and antioxidant levels decreased with
subsequent lung infections.34
Finally, with respect to geographical status and SES, a study
in 2016 showed regional variability in hospital stay duration
and risks for subsequent hospitalisations for CF patients in
the US; with the western region having longer length of
inpatient stay. Northeast had decreased risk of
hospitalisation (p=0.038), and the Caucasians in the south
had lower risk compared to African Americans (p=0.0009,
hazard ratio 0.79)35 A study in 2011 investigated the impact
of SES and found that it had little impact on the treatment
of exacerbations, but IV antibiotics were frequently
prescribed for patients with low SES.36 A cohort study in
2017 assessed the association of outcomes, including lower
SES and tobacco smoke exposure, and found that these
variables had significant correlation with decreased FEV1%
predicted, poorer lung function and nutritional decline.2

Discussion
Progressive lung disease and functional decline are chief
roots of morbidity and mortality in CF. The critical genetic
factors noted through literature review were delta F508
mutations and CFTR mutations.9,10 Homozygous
mutations showed a swift regression in pulmonary
function compared to heterozygous mutations. High-risk
genotype population for CFTR mutations showed
pronounced risk for respiratory decline.8 Severity of
mutations was addressed in two studies, showing
patients with two severe mutations manifested earlier
disease onset and severe respiratory impairment.7
Infectious agents highlighted in the studies reported
significant P. aeruginosa association with pulmonary
exacerbation and respiratory symptoms.11,12 S.
maltophilia14 and burkholderia (B.) cepacian13 were
among the other infections implicated in causing
pulmonary decline. Viral respiratory infection was
associated with exacerbations in one of the studies.15
Inflammatory biomarkers were reported as indicators of
acute exacerbations, like CRP, Leukotriene B4 (LTB4) and
IL-6.24 Calprotectin, CRP and VEGF showed a decline in
serum and sputum levels following exacerbation
treatment, implicating their role in acute episodes and a
negative correlation with FEV1.24 Sputum desmosine
levels in a study showed a positive association with
inflammation and declined following treatment.21 Also,
sCD14 levels were found to be substantially pronounced
in patients who suffered an exacerbation and exhibited a
role in predicting subsequent exacerbations.23 Overall,
biomarkers can be used to predict, measure severity and
responsiveness of treatment and tailor management.
Studies showed that patients with lower BMI and
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pancreatic insufficiency presented with severe lung
decline than pancreatic-sufficient patients. Better weight
and height were associated with less complications and
improved lung function.27 Vitamin deficiencies were
highlighted, showing a positive correlation with
pulmonary function and bouts of exacerbations. Vitamin
D was also underscored, and it was found to have an anticatabolic effect and inflammation reduction.1 In another
study, higher incidence of exacerbations and airway
inflammation was linked to vitamin D deficiency.30
Deficiencies of vitamin A, vitamin E, carotenoids and
antioxidants showed positive associations with disease
progression.33,34

diagnosis and abate grave outcomes, reducing overall
disease burden and mortality related to pulmonary
exacerbations. This can lead to an overall reduced strain
on healthcare, ensuring collective cost-effective and
efficient management of CF.

Geographic and regional variability was reported in the
US, with the western region showing increased risks and
subsequent hospitalisations compared to the northeast.35
Caucasians in the south showed lower risk relative to
African Americans. SES was emphasised in two studies,
showing that low SES and tobacco exposure had a role in
lung function decline, and antibiotics were frequently
prescribed to patients belonging to low SES.2,36
A systematic review in 2016 defined the rate of
pulmonary regression in CF and identified influencing risk
factors, while also summarising some findings about
potential risk factors similar to the current review.37
The current review, along with the mentioned factors,
analysed data describing other potential indicators, like S.
maltophilia, viral infections and certain biomarkers
showing correlations with both progression and
management of respiratory disease, stressing their role in
aiding diagnosis. We took a step forward and included
studies describing low BMI, vitamin deficiencies,
pancreatic insufficiency, and keeping pulmonary
exacerbation as the main emphasis.
The current review had certain limitations as it could not
find any study from South Asia representing the risk
factors prevalent in this region. Non-indexed journals and
grey literature were not reviewed. Despite the limitations,
however, the review calculated risk of bias for studies
using standardized tools, such as NOS and the Cochrane
risk of bias tools.5,6 Also, to our knowledge, the current
review is the first to highlight major risk factors associated
with pulmonary exacerbation that can be used as a guide
for future research. On the basis of findings, we strongly
stress the need for research in the domains of causes,
identification of risk factors, and their roles in overall
management of pulmonary exacerbations in CF cases.

Conclusion
Early detection of risk factors can result in prompt
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